S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
It's almost April 15. Here's how to reduce stress and get your taxes done
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
It's almost April 15. Here's how to reduce stress and get your taxes done
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
It's almost April 15. Here's how to reduce stress and get your taxes done
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
It's almost April 15. Here's how to reduce stress and get your taxes done
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
NASDAQ:DTIL

Precision BioSciences (DTIL) Stock Price, News & Analysis

$14.12
-0.33 (-2.28%)
(As of 04/12/2024 ET)
Today's Range
$14.00
$14.61
50-Day Range
$10.91
$18.56
52-Week Range
$8.25
$28.44
Volume
30,612 shs
Average Volume
130,709 shs
Market Capitalization
$97.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$60.00

Precision BioSciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
324.9% Upside
$60.00 Price Target
Short Interest
Bearish
8.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.99
Upright™ Environmental Score
News Sentiment
0.63mentions of Precision BioSciences in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$64,854 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.93) to ($2.87) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.81 out of 5 stars

Medical Sector

222nd out of 927 stocks

Biological Products, Except Diagnostic Industry

28th out of 157 stocks

DTIL stock logo

About Precision BioSciences Stock (NASDAQ:DTIL)

Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treatment of acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T cell candidate targeting B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma secretase inhibitor. The company has development and commercial license agreements with Les Laboratoires Servier to develop allogeneic CAR T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

DTIL Stock Price History

DTIL Stock News Headlines

Precision BioSciences Inc (DTIL)
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Precision BioSciences Inc Q4 Loss decreases, but misses estimates
Earnings Preview: Precision BioSciences
Precision BioSciences, Inc. (PBS0.F)
See More Headlines
Receive DTIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Precision BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
4/14/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:DTIL
Fax
N/A
Employees
115
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$60.00
High Stock Price Target
$60.00
Low Stock Price Target
$60.00
Potential Upside/Downside
+324.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-61,320,000.00
Net Margins
-125.84%
Pretax Margin
-87.28%

Debt

Sales & Book Value

Annual Sales
$48.73 million
Book Value
$4.53 per share

Miscellaneous

Free Float
6,563,000
Market Cap
$97.71 million
Optionable
Optionable
Beta
1.53
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Michael Amoroso (Age 45)
    President, CEO & Director
    Comp: $979.04k
  • Mr. John Alexander Kelly R.Ph. (Age 57)
    CFO & Principal Accounting Officer
    Comp: $623.58k
  • Mr. Dario Scimeca (Age 48)
    General Counsel & Secretary
    Comp: $576.43k
  • Dr. Jefferson J. Smith Ph.D. (Age 51)
    Co-Founder & Chief Research Officer
  • Mei Burris
    Director of Investor Relations & Finance
  • Mr. Bruce Stevens
    Vice President of Quality & Compliance
  • Maurissa Messier
    Senior Director of Corporate Communications
  • Ms. Juli Blanche
    Chief People Officer
  • Mr. Garrett Gincley
    Head of Manufacturing
  • Dr. Alan F. List M.D. (Age 69)
    Chief Medical Officer

DTIL Stock Analysis - Frequently Asked Questions

Should I buy or sell Precision BioSciences stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precision BioSciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DTIL shares.
View DTIL analyst ratings
or view top-rated stocks.

What is Precision BioSciences' stock price target for 2024?

2 Wall Street analysts have issued 12 month price objectives for Precision BioSciences' shares. Their DTIL share price targets range from $60.00 to $60.00. On average, they anticipate the company's stock price to reach $60.00 in the next twelve months. This suggests a possible upside of 324.9% from the stock's current price.
View analysts price targets for DTIL
or view top-rated stocks among Wall Street analysts.

How have DTIL shares performed in 2024?

Precision BioSciences' stock was trading at $10.95 at the beginning of the year. Since then, DTIL shares have increased by 28.9% and is now trading at $14.12.
View the best growth stocks for 2024 here
.

Are investors shorting Precision BioSciences?

Precision BioSciences saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 288,900 shares, an increase of 62.3% from the March 15th total of 178,000 shares. Based on an average daily volume of 139,500 shares, the days-to-cover ratio is presently 2.1 days. Currently, 8.0% of the company's stock are sold short.
View Precision BioSciences' Short Interest
.

When is Precision BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our DTIL earnings forecast
.

How were Precision BioSciences' earnings last quarter?

Precision BioSciences, Inc. (NASDAQ:DTIL) announced its earnings results on Wednesday, November, 10th. The company reported ($5.70) EPS for the quarter, beating the consensus estimate of ($17.70) by $12.00. The company earned $24.04 million during the quarter, compared to analysts' expectations of $8.54 million. Precision BioSciences had a negative trailing twelve-month return on equity of 204.66% and a negative net margin of 125.84%. During the same period in the prior year, the company earned ($15.00) earnings per share.

What ETF holds Precision BioSciences' stock?

Kelly CRISPR & Gene Editing Technology ETF holds 133,661 shares of DTIL stock, representing 2.96% of its portfolio.

When did Precision BioSciences' stock split?

Precision BioSciences's stock reverse split on Wednesday, February 14th 2024. The 1-30 reverse split was announced on Wednesday, February 14th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What is Matt Kane's approval rating as Precision BioSciences' CEO?

12 employees have rated Precision BioSciences Chief Executive Officer Matt Kane on Glassdoor.com. Matt Kane has an approval rating of 100% among the company's employees. This puts Matt Kane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Precision BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precision BioSciences investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), Alector (ALEC), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Micron Technology (MU), Homology Medicines (FIXX), Heron Therapeutics (HRTX), Inovio Pharmaceuticals (INO) and Invitae (NVTA).

When did Precision BioSciences IPO?

Precision BioSciences (DTIL) raised $126 million in an IPO on Thursday, March 28th 2019. The company issued 7,900,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays acted as the underwriters for the IPO.

How do I buy shares of Precision BioSciences?

Shares of DTIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DTIL) was last updated on 4/14/2024 by MarketBeat.com Staff

From Our Partners